公开(公告)号：US20240358821A1

公开(公告)日：2024-10-31

申请号：US18577550

申请日：2022-07-06

Applicant: The Trustees of the University of Pennsylvania

Inventor： Erin Kathleen Reagan ,  Drew Weissman

IPC: A61K39/29 ,  A61K9/127 ,  A61K9/51 ,  A61K39/00 ,  A61P31/14 ,  C12N7/00

CPC classification number: A61K39/29 ,  A61K9/127 ,  A61K9/5123 ,  A61P31/14 ,  C12N7/00 ,  A61K2039/53 ,  A61K2039/55555 ,  C12N2770/24222 ,  C12N2770/24234

Abstract: Described are compositions comprising a nucleoside-modified RNA molecules encoding a HCV p7 protein in combination with at least one additional HCV antigen, adjuvant, or a combination thereof, and their use for inducing an immune response against HCV.

公开(公告)号：US20240358819A1

公开(公告)日：2024-10-31

申请号：US18577571

申请日：2022-07-08

Applicant: ModernaTX, Inc.

Inventor： Guillaume Stewart-Jones

IPC: A61K39/215 ,  A61K9/51 ,  A61K39/00 ,  A61P37/04

CPC classification number: A61K39/215 ,  A61K9/5123 ,  A61P37/04 ,  A61K2039/53 ,  A61K2039/6075

Abstract: The disclosure relates to pan human coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.

公开(公告)号：US20240350605A1

公开(公告)日：2024-10-24

申请号：US18688336

申请日：2022-08-31

Applicant: Elixirgen Therapeutics, Inc.

Inventor： Minoru S.H. KO

IPC: A61K39/00 ,  A61K9/00 ,  A61K47/36 ,  A61P35/00 ,  C07K14/005 ,  C07K14/47 ,  C12N15/86

CPC classification number: A61K39/001189 ,  A61K9/0021 ,  A61K39/00115 ,  A61K39/001153 ,  A61K39/001186 ,  A61K39/001188 ,  A61K47/36 ,  A61P35/00 ,  C07K14/005 ,  C07K14/4748 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/70 ,  C07K2319/02 ,  C12N2770/36122 ,  C12N2770/36134 ,  C12N2770/36143 ,  C12N2810/855

Abstract: The present disclosure relates to mRNA, self-replicating RNA, and temperature-sensitive, self-replicating RNA encoding a cancer antigen. The RNA constructs are suitable for cancer immunotherapy in a mammalian subject, such as a human subject.

公开(公告)号：US20240342270A1

公开(公告)日：2024-10-17

申请号：US18265323

申请日：2021-12-03

Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

Inventor： Roy CURTISS, III ,  Soo-Young C. WANDA ,  Shifeng WANG

IPC: A61K39/215 ,  A61K39/00 ,  A61P37/04 ,  C07K14/005 ,  C12N1/20 ,  C12N15/74

CPC classification number: A61K39/215 ,  A61P37/04 ,  C07K14/005 ,  C12N1/20 ,  C12N15/74 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/53 ,  C07K2319/00

Abstract: Described within is a new much improved host-vector systems for delivery of synthesized antigens or of DNA vaccines to a diversity of animal and human hosts to elicit immune responses, especially protective immune responses to control infection and disease induction and/or transmission by bacterial, viral, parasite and fungal infectious disease agents.

公开(公告)号：US20240342269A1

公开(公告)日：2024-10-17

申请号：US17923497

申请日：2021-05-07

Applicant: TRANSLATE BIO, INC.

Inventor： Anusha DIAS ,  Khang Anh TRAN ,  Minnie ZACHARIA ,  Xiaobo GU ,  Lianne BOEGLIN ,  Joseph A. SKALESKI ,  Shrirang KARVE ,  Frank DEROSA ,  Tong-Ming FU ,  Kirill KALNIN ,  Sudha CHIVUKULA ,  Timothy PLITNIK ,  Danilo CASIMIRO ,  Jeffrey S. DUBINS

IPC: A61K39/215 ,  A61K9/51 ,  A61K39/00 ,  A61P31/14 ,  C07K14/005

CPC classification number: A61K39/215 ,  A61K9/5123 ,  A61P31/14 ,  C07K14/005 ,  A61K2039/53 ,  C12N2770/20022 ,  C12N2770/20034

Abstract: The present invention relates to optimized nucleotide sequence encoding SARS-COV-2 antigens. These sequences are particularly suitable for use in vaccine compositions for the treatment or prevention of infections caused by a β-coronaviruses, including COVID-19 infections, in a human or animal subject in need of such treatment.

公开(公告)号：US12115217B2

公开(公告)日：2024-10-15

申请号：US18512730

申请日：2023-11-17

Applicant: Trustees of Boston University

Inventor： Joshua Edward McGee ,  Jack Rainier Kirsch ,  Eric Bressler ,  Mark W. Grinstaff ,  Wilson Wong ,  Lidya Yidnekachew Sertse ,  Kexin Li

IPC: A61K39/00 ,  A61K39/02 ,  A61K39/12 ,  A61K39/155 ,  A61K39/215 ,  A61P31/04 ,  A61P37/04 ,  C07K14/005 ,  C07K14/575 ,  C07K16/28 ,  C07K16/32 ,  C12N15/86

CPC classification number: A61K39/215 ,  A61K39/4631 ,  A61P37/04 ,  C07K14/005 ,  C07K14/575 ,  C07K16/2803 ,  C07K16/32 ,  C12N15/86 ,  A61K2039/53 ,  A61K2239/23 ,  C12N2770/20022 ,  C12N2770/36143 ,  C12N2830/002 ,  C12N2830/50 ,  C12N2840/203

Abstract: The technology described herein is directed to compositions and methods for modifying and controlling the activity of cells by expression of proteins from self-amplifying RNA (saRNA). Also described herein are compositions and methods for modifying and controlling the activity of cells by expression of proteins from self-amplifying RNA that is substituted with chemically modified nucleotides.

公开(公告)号：US20240325596A1

公开(公告)日：2024-10-03

申请号：US18708518

申请日：2022-11-09

Applicant: Wisconsin Alumni Research Foundation

Inventor： Joshua CHOE ,  William MURPHY

IPC: A61L27/12 ,  A61K9/19 ,  A61K39/00 ,  A61K39/015 ,  A61K39/15 ,  A61K39/215 ,  A61K48/00 ,  A61L27/54 ,  C12N15/87

CPC classification number: A61L27/12 ,  A61K9/19 ,  A61K39/015 ,  A61K39/15 ,  A61K39/215 ,  A61K48/0025 ,  A61L27/54 ,  C12N15/87 ,  A61K2039/53 ,  A61K2039/575

Abstract: The present disclosure relates to ribonucleic acid (RNA)-based therapeutic compositions and in particular a messenger RNA (mRNA) based therapeutic composition. In one embodiment, the RNA-based therapeutic composition may include a mineral-coated substrate, RNA complexes bound to the mineral-coated substrate, and a lyoprotectant. The RNA complexes may include RNA complexed with a complexing agent. The composition may be lyophilized to a dry powder. The mineral-coated substrate may serve to stabilize and promote the transfection efficiency of the RNA complexes after lyophilization. In some embodiments, the mineral-coated substrate includes mineral-coated microparticles (MCMs). In other embodiments, the mineral-coated substrate is a mineral-coated glass vial.

公开(公告)号：US20240307526A1

公开(公告)日：2024-09-19

申请号：US18681538

申请日：2022-08-05

Applicant: NUTCRACKER THERAPEUTICS, INC.

Inventor： Colin James McKinlay

IPC: A61K39/215 ,  A61K9/127 ,  A61K39/00 ,  A61K39/12 ,  A61P37/04 ,  C07K7/06

CPC classification number: A61K39/215 ,  A61K9/1271 ,  A61K39/12 ,  A61P37/04 ,  C07K7/06 ,  A61K2039/53 ,  A61K2039/575 ,  A61K2039/585 ,  A61K2039/892

Abstract: The present disclosure provides delivery vehicle compositions comprising hydroxyethyl-capped tertiary amino lipidated cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.

公开(公告)号：US20240299526A1

公开(公告)日：2024-09-12

申请号：US18681132

申请日：2022-08-11

Applicant: Nutcracker Therapeutics, Inc.

Inventor： Samuel Deutsch ,  Daniel Frimannsson ,  Ole Haabeth ,  Pei-Ken Hsu

IPC: A61K39/12 ,  A61K39/00 ,  A61P31/14

CPC classification number: A61K39/12 ,  A61P31/14 ,  A61K2039/53 ,  C12N2770/20034

Abstract: The presently described and disclosed technology includes, in one example, a method, comprising: extracting a sequence of a spike protein of a first virus from a first non-human mammal that is previously exposed to an infection by the first virus; identifying a target antigen specific to the spike protein; and injecting an mRNA therapeutic comprising an mRNA encoding the target antigen into a human patient that has antibodies to a second virus.

公开(公告)号：US20240299525A1

公开(公告)日：2024-09-12

申请号：US18418127

申请日：2024-01-19

Applicant: ModernaTX, Inc.

Inventor： Giuseppe Ciaramella ,  Kapil Bahl ,  Amy Espeseth ,  Andrew J. Bett ,  Pedro Cejas ,  Lan Zhang ,  Christine Shaw

IPC: A61K39/12 ,  A61K9/00 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K9/0019 ,  A61K2039/53 ,  A61K2039/55555

Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.